Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid

Research output: Contribution to journalReviewResearchpeer-review

Abstract

Low-dose acetylsalicylic acid (ASA) is widely used as antithrombotic prophylaxis. Enteric coated ASA has been developed in order to decrease the risk of gastrointestinal side effects. The consequences of enteric coating on pharmacokinetics and antiplatelet effect of ASA have not systematically been assessed. This MiniReview demonstrates that data from clinical trials indicate that enteric coating can reduce the antiplatelet effect of ASA compared to plain ASA. This is possibly due to decreased bioavailability of ASA caused by prolonged solvation and absorption of the enteric coated formulations. Therefore, low dose enteric coated ASA might not be bioequivalent to plain ASA, entailing the risk of insufficient cardiovascular prophylaxis.
Original languageEnglish
JournalBasic & Clinical Pharmacology & Toxicology
Volume116
Issue number3
Pages (from-to)212-215
ISSN1742-7835
DOIs
Publication statusPublished - 2015

Cite this